Literature DB >> 1977004

Evoked potentials in assessment and follow-up of patients with Wilson's disease.

G Grimm1, W Oder, L Prayer, P Ferenci, C Madl.   

Abstract

Treatment of 9 patients with Wilson's disease was prospectively studied with evoked potentials and magnetic resonance imaging (MRI). Oral penicillamine therapy led to a decrease in auditory brainstem (ABP) and somatosensory (SEP) conduction times in 6 and 4 neurologically symptomatic patients, respectively. ABP and SEP were normal in 3 other symptom-free patients. MRI showed cerebral lesions in 4 of 7 patients. Quantified indices of brain atrophy were unaffected by treatment. ABP and SEP may reveal a reversible component of the disease that cannot be detected by MRI, and may be a more sensitive measure of treatment efficacy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977004     DOI: 10.1016/0140-6736(90)92419-i

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  9 in total

Review 1.  Neurophysiological investigation of hepatic encephalopathy.

Authors:  Piero Amodio; Angelo Gatta
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

2.  [Classification of Wilson's disease based on neurophysiological parameters].

Authors:  W Hermann; P Günther; A Wagner; T Villmann
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

Review 3.  Wilson disease.

Authors:  Reinhard Kitzberger; Christian Madl; Peter Ferenci
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

Review 4.  Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach.

Authors:  Sara Montagnese; Piero Amodio; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

Review 5.  Pathophysiology and clinical features of Wilson disease.

Authors:  Peter Ferenci
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

6.  [Electrophysiological impairment profile of patients with Wilson's disease].

Authors:  W Hermann; T Villmann; A Wagner
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

7.  Wilson's disease with cerebral manifestation: monitoring therapy by CSF copper concentration.

Authors:  C Hartard; B Weisner; C Dieu; K Kunze
Journal:  J Neurol       Date:  1993-12       Impact factor: 4.849

8.  Relationship between striatal glucose consumption and copper excretion in patients with Wilson's disease treated with D-penicillamine.

Authors:  H Hefter; T Kuwert; H Herzog; G Arendt; W Stremmel; L E Feinendegen
Journal:  J Neurol       Date:  1993-11       Impact factor: 4.849

Review 9.  Clinical neurophysiology of hepatic encephalopathy.

Authors:  Piero Amodio; Sara Montagnese
Journal:  J Clin Exp Hepatol       Date:  2014-08-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.